Ustekinumab biosimilar europe launch date stelara patent expiry?

Short answer (as of my last update in 2024):
- EU launch of ustekinumab (Stelara) biosimilars: None had launched in Europe yet. Several biosimilar candidates were in late-stage development or regulatory review, but a market entry date in the EU had not been established by mid-2024. Launch timing will depend on patent expiry and regulatory approvals, so any date is uncertain and country-dependent.
- Stelara patent expiry in Europe: The patent landscape for ustekinumab in Europe is complex, with multiple patent families and data/ SPC protections. There isn’t a single Europe-wide expiry date. Some core patents may have expired in some jurisdictions by the early-to-mid 2020s, but additional protections (SPCs and other patents) can extend exclusivity in various EU markets. For a precise expiry date, you’d need to look up the specific patent families in the European Patent Register and confirm the SPC status in each EU country.

If you’d like, I can look up the latest, country-by-country patent expiry dates and the current status of EU biosimilar applications. Just tell me and I’ll fetch the most up-to-date sources.